In the race to the Covid-19 vaccine, the progress that has now led to New Zealand’s first jab on Friday has seen several of the biotech world’s largest players fall flat, while others that had never had a vaccine approved before have rocketed into the global consciousness.
Shares in GSK,
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly
credit card debit
